HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced it has reinforced its intellectual property protections around combination therapies using its XTRAC excimer laser with systemic and biologic drugs, a move the company says will expand treatment options for inflammatory and autoimmune skin conditions while securing long-term market exclusivity.
The company holds three patents central to this strategy. One is a global patent covering the combined use of excimer laser therapy with systemic drugs for localized skin treatment. In the U.S., two additional patents cover pairing the technology with JAK inhibitors and biologic drugs, respectively. Together, these patents aim to establish STRATA’s leadership in combination approaches that merge precision phototherapy with immune-modulating medications.
“Foundational to this long-term growth initiative are our prescient investments in our Intellectual Property and technology, ensuring broad protection and market exclusivity,” said Dr. Dolev Rafaeli, President and CEO of STRATA Skin Sciences. He added that the patents will play a critical role in protecting future market share as the company continues to expand clinical applications.
The XTRAC excimer laser delivers targeted UVB light, enabling high-dose treatment directly to affected skin while minimizing exposure to surrounding tissue. When combined with systemic therapies such as biologics or JAK inhibitors, STRATA says the approach can extend remission, reduce drug dosages, and enhance safety. Conditions targeted by these therapies include psoriasis, atopic dermatitis, vitiligo, leukoderma, and alopecia areata.
The company is also positioning its technology for broader reimbursement opportunities. Earlier this year, the American Medical Association’s CPT Editorial Panel approved updates expanding excimer laser billing codes to include all inflammatory and autoimmune skin conditions beginning in 2027. STRATA is working to accelerate the timeline by securing temporary CMS codes that could bring reimbursement eligibility as early as 2026.
Executives say the expanded coding could triple the company’s addressable patient base, improving treatment economics for both providers and the business. STRATA also highlighted ongoing litigation with competitor LaserOptek, noting it expects to recover damages and secure injunctive relief to further protect its investments in the excimer laser market.
By strengthening its patent portfolio and pursuing earlier reimbursement, STRATA is positioning itself at the forefront of integrative dermatology, combining device-based precision with systemic therapies to address complex skin conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.